InterVenn Biosciences, also identified as Venn Biosciences, is a biotechnology company focused on applying glycoproteomics to challenging questions in women’s health. Its work extends beyond genomics and traditional proteomics, using artificial intelligence alongside glycoproteomic analysis to map glycoprotein control points involved in disease progression. The company says this approach can reveal biological insights that genomics and proteomics alone may not detect.

InterVenn applies its research to conditions including ovarian cancer and endometriosis, aiming to advance understanding and support the evolution of healthcare. Its offerings include the GlycoKnow™ platform and glycoproteomic insights that the company invites partners to integrate into clinical workflows. It also seeks research collaborators interested in exploring new applications of its technology.

For professionals and others following its work, InterVenn provides technical updates, clinical trial results and company news through a subscription option. The company presents its mission as exploring a new frontier in biology and encourages researchers and healthcare partners to engage with its platform and research.